Abstracts Archive - Page 1810 of 2607 - ACR Meeting Abstracts

Abstract Number: 3170 • 2016 ACR/ARHP Annual Meeting
Association Between Insulin Resistance, Subclinical Artheriosclerosis and Activity/Damage Status in Systemic Lupus Erythematosus Patients
Hiurma Sanchez-Perez¹, Beatriz Tejera² and Ivan Ferraz-Amaro³, ¹Rheumatology, Rheumatology Division, Hospital Universitario de Canarias, La Laguna, Spain, ²Rheumatology Division, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ³Rheumatology, Rheumatology Division, Hospital Universitario de Canarias, Tenerife, Spain
Background/Purpose: Insulin resistance (IR) may contribute to an increase in cardiovascular risk. The aim of this study was to examine the association between IR and…
Abstract Number: 3171 • 2016 ACR/ARHP Annual Meeting
The Impact of Statin Use on Mortality in Systemic Autoimmune Rheumatic Diseases
April Jorge, Na Lu and Hyon K. Choi, Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Individuals with systemic autoimmune rheumatic diseases (SARDs)—such as systemic lupus erythematosus (SLE) and systemic sclerosis (SSc)—have been found to have an increased risk of…
Abstract Number: 3172 • 2016 ACR/ARHP Annual Meeting
Temporal Trends in SLE Mortality According to Sex, Race, Ethnicity, and Geographic Region in the United States over the Past Five Decades
Eric Yen¹, Magda Shaheen², Jennifer MP Woo¹, Neil Mercer¹, Lewei Duan¹, Ning Li¹, Arun Karlamangla¹, Deborah K. McCurdy¹ and Ram R. Singh¹, ¹UCLA, Los Angeles, CA, ²Charles R. Drew University of Medicine and Science, Los Angeles, CO
Background/Purpose: Over the past half-century, diagnostic and therapeutic developments for SLE have led to dramatic improvements in the 5- and 10-year survival. Whether these achievements…
Abstract Number: 3173 • 2016 ACR/ARHP Annual Meeting
Pan-PPAR Agonist IVA337 Is Effective in the Prevention of Experimental Lung Fibrosis and Related Pulmonary Hypertension
Jerome Avouac¹, Irena Konstantinova², Christophe Guignabert³, Sonia Pezet⁴, Anne Cauvet⁵, Jeremy Sadoine⁶, Thomas Guilbert⁴, Jean-Michel Luccarini⁷, Jean-Louis Junien⁷, Pierre Broqua⁷ and Yannick Allanore⁸, ¹Rheumatology A department and INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ²Inventiva, Daix, France, ³Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France, ⁴Institut Cochin, INSERM U1016, Paris, France, ⁵INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ⁶Equipe d’Accueil (EA) 2496 Pathologie, Imagerie et Biothérapies Orofaciales, Faculty of Odontology, Paris Descartes University, Montrouge, France, ⁷Inventiva, DAIX, France, ⁸Rheumatology, Paris Descartes University, Paris, France
Background/Purpose: Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors known to modulate fibrosis. The pan-PPAR agonist IVA337 recently demonstrated efficacy in prevention and treatment of experimental…
Abstract Number: 3174 • 2016 ACR/ARHP Annual Meeting
Apremilast Attenuates the Fibrogenic Phenotype of Dermal Fibroblasts from Patients with Systemic Sclerosis, Contributing to the Prevention of the Progression of Experimental Dermal Fibrosis
Tomoaki Higuchi¹, Yasushi Kawaguchi², Kae Takagi³, Akiko Tochimoto², Yuki Ichimura², Yasuhiro Katsumata², Hisae Ichida², Hidenaga Kawasumi², Hirokazu Nishina², Mari Tochihara², Akira Nishino², Shinya Hirahara², Rina Moriyama² and Hisashi Yamanaka⁴, ¹Institute Of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Medicine, Tokyo Women's Medical University medical Center East, Tokyo, Japan, ⁴Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is a chronic fibrosing disorder that affects the skin and other internal organs. Inflammation, vasculopathy and fibrosis at the affected area…
Abstract Number: 3175 • 2016 ACR/ARHP Annual Meeting
Longitudinal Analysis of MMF Clinical, Molecular, and Immunohistochemistry (IHC) Responses Shows SSc Patients Lose Their Inflammatory Signature and Rebound upon Treatment Cessation
Diana Toledo¹, Monique Hinchcliff², Jaclyn Taroni¹, Tammara A. Wood³, Jennifer Franks³, Sanjiv Shah⁴, Rishi Agrawal⁴, Lauren Beussink-Nelson⁴, Mary A. Carns⁵, Sofia Podlusky⁶, Patricia Pioli⁷ and Michael Whitfield³, ¹Department of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ³Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Northwestern University, Chicago, IL, ⁵Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL, ⁶Rheumatology Feinberg School of Medicine, Northwestern University, Chicago, IL, ⁷Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: We previously showed patients in the inflammatory subset were most likely to demonstrate improvement in modified Rodnan Skin Score (mRSS) during mycophenolate mofetil (MMF)…
Abstract Number: 3176 • 2016 ACR/ARHP Annual Meeting
Meta-Analysis of SSc Clinical Trials with Molecular Gene Expression Data Suggests Potential Combination Therapies
Jaclyn N. Taroni¹, Viktor Martyanov² and Michael L. Whitfield², ¹Department of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Clinical trials in SSc have tended to be underpowered and not meet clinical endpoints. Genome-wide gene expression measured in some studies can prove challenging…
Abstract Number: 3177 • 2016 ACR/ARHP Annual Meeting
Targeted Nuclear Imaging for the Early Detection of Lung Involvement in Systemic Sclerosis
Janine Schniering¹, Stephanie Haller², Zhongning Guo¹, Martina Benesova^2,3, Carol A. Feghali-Bostwick⁴, Roger Schibli^2,3, Oliver Distler⁵, Cristina Müller^2,3 and Britta Maurer⁵, ¹Department of Rheumatology, University Hospital Zurich, Schlieren, Switzerland, ²Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen PSI, Switzerland, ³Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, Zurich, Switzerland, ⁴Medicine, Medical University of South Carolina, Charleston, SC, ⁵Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is one of the main causes of systemic sclerosis (SSc)-related deaths. Since routine diagnostics such as high resolution computed tomography…
Abstract Number: 3178 • 2016 ACR/ARHP Annual Meeting
Heart Dysfunction in Systemic Sclerosis: Involvement of a Novel Fibrogenic Stromal Cell Subset
Mara Stellato¹, Michal Rudnik¹, Florian Renoux², Elena Pachera¹, Karl Sotlar³, Karin Klingel⁴, Joerg C. Henes⁵, Przemyslaw Blyszczuk⁶, Oliver Distler¹ and Gabriela Kania¹, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Depertment of Rheumatology, University Hospital Zurich, Schlieren, Switzerland, ³Institute of Pathology, Ludwig Maximilians University, Munich, Germany, ⁴Department of Molecular Pathology, University Hospital Tuebingen, Tuebingen, Germany, ⁵Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ⁶Cardioimmunology, Center of Molecular Cardiology, University of Zurich, 8952 Schlieren, Switzerland
Background/Purpose: Cardiac dysfunction is a significant cause of the high mortality in systemic sclerosis (SSc). Heart involvement in SSc patients resembles inflammatory dilated cardiomyopathy (iDCM)…
Abstract Number: 3179 • 2016 ACR/ARHP Annual Meeting
Scale Structure and Measurement Properties of a Disease Specific Patient-Reported Outcome for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Joanna C. Robson^1,2,3, Jill Dawson⁴, Judy A. Shea⁵, Helen Doll⁶, Susan Ashdown⁷, Renee Borchin⁸, Ebony Easley⁹, John T. Farrar¹⁰, Don Gebhart¹¹, Katherine Kellom¹², Georgia Lanier¹³, Raashid Luqmani¹⁴, Carol A McAlear¹⁵, John Mills¹⁶, Nataliya Milman^17,18,19, Jacqueline Peck⁷, Gunnar Tomasson²⁰, Peter F. Cronholm⁹ and Peter A. Merkel²¹, ¹Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom, ²Department of Rheumatology, University Hospitals Bristol NHS Trust, Bristol, United Kingdom, ³School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, ⁴Nuffield Department of Population Health HSRU, University of Oxford, Oxford, United Kingdom, ⁵Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Department of Population Health, University of East Anglia, Norwich, United Kingdom, ⁷Oxford, Oxford, United Kingdom, ⁸University of South Florida, Tampa, FL, ⁹Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Columbus, Columbus, OH, ¹²PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, United Kingdom, ¹³NONE, Framingham, MA, ¹⁴NDORMS , Rheumathology, Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ¹⁵Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁶Vasculitis UK, Sheffield, United Kingdom, ¹⁷Department of Medicine, University of Ottawa, Ottawa, ON, Canada, ¹⁸The Ottawa Hospital, Ottawa, ON, Canada, ¹⁹Department of Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, ON, Canada, ²⁰Dept of Public Health Sciences, University of Iceland, Reykjavik, IS, ²¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Candidate questionnaire items were produced following in-depth qualitative research in the UK, US, and Canada plus cognitive interviews, extensive piloting and independent linguistic and…
Abstract Number: 3180 • 2016 ACR/ARHP Annual Meeting
Utility of Measurements of Urinary Soluble CD163 & MCP-1 in the Identification of Subtle Renal Flares in ANCA-Associated Vasculitis
Sarah M Moran¹, Michelle Ryan¹, Paul A. Monach², David Cuthbertson³, Simon Carette⁴, Jean Dunne⁵, Gary S. Hoffman⁶, Nader A. Khalidi⁷, Curry L. Koening⁸, Carol A. Langford⁹, Carol A. McAlear¹⁰, Larry W. Moreland¹¹, Christian Pagnoux⁴, Philip Seo¹², Ulrich Specks¹³, Antoine G. Sreih¹⁴, Steven R. Ytterberg¹⁵, Lina Zgaga¹⁶, Peter A. Merkel¹⁷, Mark A. Little¹⁸ and the Vasculitis Clinical Research Consortium, ¹Clinical Medicine, Trinity Health Kidney Centre, Dublin, Ireland, ²Rheumatology, Boston University School of Medicine, Boston, MA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Immunology Department, St James's Hospital, Dublin, Ireland, ⁶Rheumatology, Cleveland Clinic, Cleveland, OH, ⁷McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁸Rheumatology, University of Utah, Salt Lake City, UT, ⁹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹²Medicine, Johns Hopkins University, Baltimore, MD, ¹³Mayo Clinic, Rochester, MN, ¹⁴Rheumatology, The University of Pennsylvania, Philadelphia, PA, ¹⁵Rheumatology, Mayo Clinic, Rochester, MN, ¹⁶Public Health and Primary Care, Trinity College Dublin, Dublin, Ireland, ¹⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁸Clinical Medicine, Trinity College Dublin, Dublin, Ireland
Background/Purpose: Prior work has shown that urinary soluble CD163 (usCD163) displays excellent biomarker characteristics for detection of active renal vasculitis using samples from patients with…
Abstract Number: 3181 • 2016 ACR/ARHP Annual Meeting
The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis
Rennie L. Rhee¹, John C. Davis², Linna Ding³, Fernando Fervenza⁴, Gary S. Hoffman⁵, Cees G.M. Kallenberg⁶, Carol A. Langford⁷, W Joseph McCune⁸, Paul A. Monach⁹, Philip Seo¹⁰, Robert F. Spiera¹¹, Eugene William St.Clair¹², Ulrich Specks⁴, John H. Stone¹³ and Peter A. Merkel¹⁴, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Baxalta, Cambridge, MA, ³NIH, Bethesda, MD, ⁴Mayo Clinic, Rochester, MN, ⁵Rheumatology, Cleveland Clinic, Cleveland, OH, ⁶Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁷Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Medicine, Johns Hopkins University, Baltimore, MD, ¹¹Hospital for Special Surgery, Cornell, New York, NY, ¹²Rheumatology and Immunology, Duke University, Durham, NC, ¹³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹⁴Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA
Background/Purpose: The significance of persistent hematuria or proteinuria in patients with ANCA-associated vasculitis (AAV) who are in clinical remission is still unclear. This study…
Abstract Number: 3182 • 2016 ACR/ARHP Annual Meeting
Attenuation of Fluorine-18-Fluorodeoxyglucose Uptake in Large Vessel Giant Cell Arteritis after Short-Term High-Dose Steroid Treatment – a Diagnostic Window of Opportunity
Berit Dalsgaard Nielsen¹, Ib Tønder Hansen², Kresten Krarup Keller³, Philip Therkildsen⁴, Ellen-Margrethe Hauge³ and Lars Christian Gormsen⁵, ¹Rheumatology, Department of Rheumatology, Aarhus University Hospital, Århus C, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus C, Denmark, ⁵Nuclear Medicine and PET Center, Department of Nuclear Medicine and PET Center, Aarhus University Hospital, Århus C, Denmark
Background/Purpose: Fluorine-18-fluorodeoxyglucose (18F-FDG) PET/CT is, due to its excellent diagnostic accuracy[1], increasingly used to diagnose large vessel GCA (LV-GCA). However, PET/CT is not always readily…
Abstract Number: 3183 • 2016 ACR/ARHP Annual Meeting
Tocilizumab for the Treatment of Giant Cell Arteritis – MR-Angiography Results from the First Randomized Placebo-Controlled Trial
Stephan Reichenbach^1,2, Sabine Adler³, Jennifer Cullmann⁴, Harald Bonel⁴, Stefan Kuchen⁵, Felix Wermelinger¹, Diana Dan¹, Michael Seitz¹ and Peter M. Villiger¹, ¹Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland, ²Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, ³Rheumatology, Immunology, Allergology, University Hospital Bern, Bern, Switzerland, ⁴Department of Diagnostic, Interventional and Pediatric Radiology, University Hospital Bern, Bern, Switzerland, ⁵Rheumatology, Immunology, and Allergology, University of Bern, Bern, MD, Switzerland
Background/Purpose: As published in The Lancet online, March 4, 2016, the first randomized, placebo-controlled trial (RCT) of tocilizumab (TCZ) in giant cell arteritis (GCA) showed…
Abstract Number: 3184 • 2016 ACR/ARHP Annual Meeting
Antiphospoholipid Antibodies in Giant Cell Arteritis. What Can They Tell Us?
Alojzija Hocevar, Rok Jese, Ziga Rotar, Polona Žigon, Saša Čučnik and Matija Tomšič, Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: The aim of our prospective study was to evaluate the potential impact of the antiphospholipid antibodies (aPL-Abs) on the clinical presentation of giant cell…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].